SCHEMBL6986707

SCHEMBL6986707

CC(C(=O)N1CCCc2cc(N)ccc21)c1cccc(C#N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.44
PDK2 Q15119 2/20 0.44
PDK3 Q15120 2/20 0.44
PDK4 Q16654 2/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
HTT P42858 1/20 0.42
LMNA P02545 1/20 0.42
RIPK1 Q13546 2/20 0.41
BRD4 O60885 1/20 0.41
ATAD2 Q6PL18 1/20 0.41
CYP11B2 P19099 1/20 0.40
TSHR P16473 2/20 0.40
AVPR2 P30518 1/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6986711 0.75 TSHR (0.45) PDK1PDK2PDK3PDK4MEN1
SCHEMBL7416330 0.71 NOTUM (0.62) PDK1PDK2PDK3PDK4LMNA
SCHEMBL20899580 0.70 PDK1 (0.61) PDK1PDK2PDK3PDK4MEN1
SCHEMBL4299468 0.69 NOTUM (0.59) MEN1KMT2ALMNACYP11B2TSHR
SCHEMBL6979722 0.69 TP53 (0.48) PDK1PDK2PDK3PDK4MEN1
SCHEMBL934609 0.69 ADRA1D (0.50)
SCHEMBL28771923 0.67 RAB9A (0.65) PDK1PDK2PDK3PDK4MEN1
SCHEMBL1990381 0.67 PTGS1 (0.54) LMNAHSD17B10ALDH1A1HPGDMAPT
SCHEMBL7959087 0.67 TP53 (0.48) PDK1PDK2PDK3PDK4MEN1
SCHEMBL8809305 0.66 KDM4E (0.58) PDK1PDK2PDK3PDK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed